FDA Approves Pembrolizumab and Berahyaluronidase alfa-pmph for Subcutaneous Injection By Ogkologos - October 2, 2025 257 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Study MK-3475A-D77 Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR How can we diagnose more cancers earlier? July 27, 2021 97-Year-Old Cancer Survivor Credits Her Success With Wanting To Attend A... October 28, 2021 Veteran Avoided The Barber For 6 Years After He Left The... February 28, 2020 Diverse Genomic and Histologic Mechanisms of Resistance to KRASG12C Inhibition Described June 25, 2021 Load more HOT NEWS Largest Study on Frequent Aspirin Use Supports Reduction in Ovarian Cancer... Safety Analysis Shows that Durvalumab Treatment After SBRT Is Feasible in... Young District Attorney Diagnosed with Breast Cancer Encourages Others to Get... Pattern of DNA Damage Links Colorectal Cancer and Diet High in...
